Permanent Atrial Fibrillation: When Single-Agent Rate Control Is Not Enough

Clinical Scenario

This protocol applies to patients with permanent atrial fibrillation — AF for which no further attempts at restoration of sinus rhythm are planned, following a shared decision between patient and physician. The sole management focus is achieving and sustaining adequate heart rate control.

Previous Treatment & Why It Was Insufficient

The prior step — rate control with a single agent (a beta-blocker, digoxin, diltiazem, or verapamil) — did not achieve the target resting heart rate below 110 b.p.m., or symptoms persisted despite monotherapy. This protocol represents the escalation taken after that single-drug approach falls short.

Next-Step Approach (Partial Overview)

The next step involves combination rate control therapy, with agents selected according to the patient's individual cardiac profile, while actively avoiding bradycardia. Which combination is appropriate — and for whom — is detailed in the full protocol.

Clinical Goal

Resting heart rate below 110 b.p.m. as an initial lenient target, with stricter control reserved for patients with continuing symptoms.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/eurheartj/ehae176

AF for which no further attempts at restoration of sinus rhythm are planned, after a shared decision between the patient and physician.
Combination rate control therapy should be considered if a single drug does not control symptoms or heart rate in patients with AF, providing that bradycardia can be avoided, to control heart rate and reduce symptoms.
Note that the combination of beta-blockers with diltiazem or verapamil should only be used under specialist advice, and monitored with an ambulatory ECG to check for bradycardia.
Lenient rate control with a resting heart rate of <110 b.p.m. should be considered as the initial target for patients with AF, with stricter control reserved for those with continuing AF-related symptoms.

View source ↗